V
CRMD icon

Veritable’s CorMedix CRMD Stock Holding History

Veritable’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-53,550
Closed -$215K – 816
2022
Q2 		$215K Buy
+53,550
New +$199K ﹤0.01% 790

Other funds holding CRMD

Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Veritable's CRMD Position: Q3 2022 in Review

Veritable sold out of CorMedix (CRMD) in Q3 2022, closing a stake of 53,550 shares — an estimated $215K sold.

Veritable first reported a position in CRMD in Q2 2022 and held it in 1 quarter. The position peaked at $215K in Q2 2022. 73 funds tracked by Wall St. Rank hold CRMD as of Q3 2022.

  • Veritable reported no remaining CorMedix position as of Q3 2022 after selling out during the quarter.
  • Veritable sold 53,550 CorMedix shares in Q3 2022, an estimated $215K.
  • Veritable first reported a position in CorMedix in Q2 2022 and held it in 1 quarter.
  • Veritable's CorMedix position peaked at $215K in Q2 2022.
  • 73 funds tracked by Wall St. Rank held CorMedix as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.